Neubauer, Markus
Otahal, Alexander
Kuten, Olga
Sherman, Seth Lawrence
Moser, Lukas
Kramer, Karina
DeLuna, Andrea
Neugebauer, Johannes
Dammerer, Dietmar
Muellner, Thomas
Nehrer, Stefan http://orcid.org/0000-0001-8008-2226
Funding for this research was provided by:
Karl Landsteiner Privatuniversität für Gesundheitswissenschaften (SF25 - 500330025 -2020)
Danube University Krems University for Continuing Education
Article History
Received: 29 January 2023
Accepted: 6 August 2023
First Online: 30 August 2023
Declarations
:
: Approval was granted by the Commission for Scientific Integrity and Ethics Karl Landsteiner University Krems (EC Nr: 1022/2020).
: Informed consent was obtained from all individual participants who donated tissue that was used for the study.
: Z.L. owns stocks in the company OrthoSera GmbH, which holds patents on the hyperacute serum. O.K. and Z.L. are partly employed by OrthoSera GmbH. S.N. is part of the advisory board of OrthoSera GmbH, a startup and academic spin-off company developing hyperacute serum technology towards clinical applications. The other authors do not have to declare any conflict of interest.